Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
891.8 USD | +0.97% | -0.91% | +1.56% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.56% | 95.28B | |
-2.73% | 103B | |
+1.46% | 22.15B | |
-16.57% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.95% | 16.05B | |
+5.26% | 13.68B | |
+33.88% | 12.17B | |
-24.88% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept